Nations Financial Group Inc. IA ADV Purchases 1,167 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Nations Financial Group Inc. IA ADV boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,659 shares of the medical instruments supplier’s stock after buying an additional 1,167 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in LeMaitre Vascular were worth $2,069,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LMAT. Raymond James Financial Inc. bought a new stake in shares of LeMaitre Vascular in the 4th quarter valued at approximately $14,900,000. Invesco Ltd. lifted its stake in shares of LeMaitre Vascular by 34.5% in the 1st quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier’s stock valued at $19,753,000 after purchasing an additional 60,438 shares during the last quarter. Nuveen LLC bought a new stake in shares of LeMaitre Vascular in the 1st quarter valued at approximately $4,631,000. GAMMA Investing LLC lifted its stake in shares of LeMaitre Vascular by 7,486.5% in the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier’s stock valued at $4,519,000 after purchasing an additional 53,154 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of LeMaitre Vascular by 96.8% in the 4th quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier’s stock valued at $8,853,000 after purchasing an additional 47,250 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Barrington Research raised LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 price objective for the company in a research note on Wednesday, August 6th. Cantor Fitzgerald raised their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $98.00.

LeMaitre Vascular Trading Up 0.1%

LMAT opened at $95.91 on Friday. The stock’s fifty day moving average is $84.56 and its two-hundred day moving average is $86.53. The company has a market capitalization of $2.17 billion, a P/E ratio of 46.56, a PEG ratio of 2.46 and a beta of 0.79. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. LeMaitre Vascular’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the business posted $0.52 EPS. Analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 38.83%.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 100,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at $161,492,050.53. This trade represents a 5.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the sale, the director directly owned 2,916 shares of the company’s stock, valued at approximately $274,104. This represents a 46.16% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 202,082 shares of company stock valued at $18,249,066. 9.50% of the stock is owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.